There are currently 188 clinical trials in Overland Park, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including Menorah Medical Center, University of Kansas Cancer Center-Overland Park, Saint Luke's South Hospital and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
NCT04992780
Recruiting
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas
Conditions: Non Small Cell Lung Cancer Stage
Register for Updates
PREHEVBRIO Pregnancy Outcomes Registry
NCT06097312
Recruiting
The registry is an observational surveillance program designed to recruit and encourage participation of women who were exposed to PREHEVBRIO® hepatitis B vaccine during pregnancy and to collect and analyze information related to post-exposure pregnancy and fetal and neonatal outcomes. The objective of the Registry is to monitor and evaluate all received reports of PREHEVBRIO® vaccine exposure within 28 days prior to conception or at any time during pregnancy and delivery, as well as maternal,... Read More
Gender:
Female
Ages:
All
Trial Updated:
11/30/2023
Locations: ProPharma, Recruiting Nationwide, Overland Park, Kansas
Conditions: Vaccine Exposure During Pregnancy
Register for Updates
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
NCT04467801
Recruiting
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas
Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Register for Updates
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas +1 locations
Conditions: Breast Cancer
Register for Updates
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02302742
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
All
Ages:
All
Trial Updated:
05/08/2023
Locations: Menorah Medical Center, Overland Park, Kansas +2 locations
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Overland Park, Kansas
Conditions: Cystic Fibrosis
Register for Updates
A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults
NCT05721287
Recruiting
This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
01/31/2023
Locations: Altasciences Clinical Kansas, Overland Park, Kansas
Conditions: Pain, Acute Pain
Register for Updates
IISART (International Industry Society of Advanced Rehabilitation Technology) Advanced Rehabilitation Technology Study
NCT05652946
Recruiting
A pre-post, randomized control trial comparing cost-effective and functional outcomes of participants with neurological diagnoses using robotic devices and advanced technology during inpatient rehabilitation to the outcomes of control participants without the use of robotic devices and advanced technology during rehabilitation. We aim to show at least similar inpatient rehabilitation outcomes and improved health economics in participants with neurological diagnoses by using robotic devices and a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2022
Locations: Rehabilitation Hospital of Overland Park, Overland Park, Kansas
Conditions: Neurologic Disorder
Register for Updates